Application No. Applicant(s) 09/645.078 BISTRUP ET AL. Interview Summary Art Unit Examiner Marjorie A. Moran 1631 All participants (applicant, applicant's representative, PTO personnel): (1) Marjorie A. Moran. (2) Paula Borden. Date of Interview: 30 September 2002. Type: a) ☐ Telephonic b) ☐ Video Conference c) Personal [copy given to: 1) applicant 2) applicant's representative] Exhibit shown or demonstration conducted: d) Yes e) No. If Yes, brief description: _____. Claim(s) discussed: 1-3. Identification of prior art discussed: SPIRO. Agreement with respect to the claims f) was reached. g) was not reached. h) \square N/A. Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet . (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The examiner informed Ms. Borden that SEQ ID NO's 2 and 4, based on a search using a CRF from a parent case, appeared to be free of the prior art, and asked if applicants wanted to file a preliminary amendment reciting those SEQ ID NO's in order to facilitate prosecution and possible allowance. Ms. Borden faxed proposed claims to the examiner, but no agreement as to entry/allowability of the claims was reached. The examiner stated that a first office action on the merits would be mailed upon compliance with sequence requirements.

FACSIMILE TRANSMITTAL

BOZICEVIC, FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200 Menlo Park, CA 94025 Telephone: (650) 327-3400

Facsimile Number: (650) 327-3231

Date:

September 30, 2002

To:

ATTN: Examiner Marjorie Moran

Facsimile No.:

(703) 746-5257

From:

Paula Borden

Bozicevic, Field & Francis

(650) 833-7710

Re:

U.S. Patent Application No. 09/645,078

Message:

Please see attached claims.

Total number of pages, including this cover sheet: 3

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of the above message or the accompanying documents is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile, and mail the original to us at the above address. Thank you.

Please contact Paula Borden at (650)-833-7710 if you have any problems receiving this transmission.

١

PROPOSED CLAIMS 09/645,078 UC REF.: 98-299-3 MOFO REF.: 52944-20004.21 BF&F REF.: UCAL-107 CIP2

Cancel claims 1 and 3-15 without prejudice to renewal.

- 1. (Canceled) HEC-GlcNAc6ST present in other than its natural environment.
- 2. (Amended) [The] An HEC-GleNAc6ST polypeptide present in other than its natural environment [according to Claim 1], wherein said HEC-GleNAc6ST is human HEC-GleNAc6ST [or mouse HEC-GleNAc6ST].
- (Canceled) A fragment of the HEC-GlcNAc6ST according to Claim 1.
- -- 16. (New) The HEC-GlcNAc6ST polypeptide of claim 2, wherein said polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to human HEC-GlcNAc6ST.
- 17. (New) The HEC-GlcNAc6ST polypeptide of claim 2, wherein said polypeptide has at least 60% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:02.
- 18. (New) The HEC-GlcNAc6ST polypeptide of claim 2, wherein said polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:02.
- 19. (New) The HEC-GlcNAc6ST polypeptide of claim 2, wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:02.

- 20. (New) An HEC-GlcNAc6ST polypeptide present in other than its natural environment, wherein said HEC-GlcNAc6ST is mouse HEC-GlcNAc6ST.
- 21. (New) The HEC-GlcNAc6ST polypeptide of claim 20, wherein said polypeptide comprises a sequence having at least 75% amino acid sequence identity to mouse IIEC-GlcNAc6ST.
- 22. (New) The HEC-GlcNAc6ST polypeptide of claim 2, wherein said polypeptide comprises an amino acid sequence having at least 60% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:04.
- 23. (New) The HEC-GlcNAc6ST polypeptide of claim 20, wherein said polypeptide comprises an amino acid sequence having at least 75% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:04.
- 24. (New) The HEC-GlcNAc6ST polypeptide of claim 20, wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:04.

F:\DOCUMENT\UCAL\107cip2\Proposed claims.doc